Enzymatic Degradation Prevention

Enzymatic degradation prevention addresses biopharmaceutical stability against serum proteases, peptidases, and esterases compromising therapeutic efficacy. Protease-resistant amino acid substitutions including D-amino acids or non-natural alternatives reduce susceptibility. Modified peptide backbones replacing amide linkages with non-hydrolysable alternatives enhance stability. Cyclisation constrains peptide structure reducing protease access.

Regulatory submissions justify stability-enhancing modifications ensuring safety and tolerability. Metabolite identification confirms degradation pathways guiding prevention strategies. Combination with protease inhibitors provides additional degradation protection. Formulation excipients including polyols and surfactants stabilise biopharmaceuticals. Emerging pegylation and glycosylation technologies enhance intrinsic protease resistance.